<DOC>
	<DOCNO>NCT02061696</DOCNO>
	<brief_summary>The goal research study observe clinical safety , effectiveness patient satisfaction AXERA 2 Access System subject undergoing coronary angiographic possible Percutaneous Coronary Intervention ( PCI ) femoral artery compare standard manual compression .</brief_summary>
	<brief_title>ARISTOCRAT-A Randomized Controlled Trial Evaluating Closure Following Access With AXERA ( Device Name ) 2 Access System</brief_title>
	<detailed_description>The study single center 1:1 randomize control trial subject undergoing coronary angiography PCI . It anticipate enrollment period study two year . The post procedure follow period 37 day follow procedure .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Subject 18 85 year age . Cardiac catheterization procedure indicate involve access 5 French ( F ) 6 French ( F ) introducer femoral artery . Subject able ambulate without assistance prior procedure expect ambulate ( 20 foot ) postprocedure . Subject legally authorize representative sign informed consent . Subject unable routinely 20 foot without assistance ( e.g . require walker wheelchair mobilize paralysis ) Subject active systemic cutaneous infection inflammation ( e.g . ( septicemia time procedure ) . Subject undergoing emergent urgent cardiac catheterization acute myocardial infarction . Extensive calcification femoral artery see fluoroscopy . Subject systemic hypertension unresponsive treatment ( &gt; 180mm Hg systolic &gt; 110mm Hg diastolic ) . Subject receive thrombolytic therapy within 72 hour prior catheterization . Subject know bleeding disorder , Factor 5 deficiency , Idiopathic thrombocytopenic purpura ( ITP ) , thrombasthenia , Von Willebrand 's disease . Is warfarin International Ratio ( INR ) &gt; 1.5 . Platelet count &lt; 100,000 . Anemia ( Hemoglobin &lt; 10 g/dl Hematocrit &lt; 30 % ) . Subject compromised femoral artery access site . Subject procedure require introducer sheath size &gt; 6 French ( F ) . Subject prior vascular surgery vascular graft femoral artery access site . Subject present hemodynamic instability need emergent surgery . Subject receive femoral artery closure target access vessel collagen/PEG closure device within 90 day . Subject preexist severe noncardiac systemic disease illness result expect life expectancy &lt; 1 year . Subject participate investigational drug another device research study interfere current research study endpoint . Pregnant lactating subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Coronary Disease</keyword>
	<keyword>Heart disease</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Arteriosclerosis</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Manual Compression</keyword>
</DOC>